Form 4: Amylyx Co-CEO Sells Shares for Tax Obligations

Amylyx Pharmaceuticals Co-CEO Justin B. Klee sold 7,715 shares of common stock at a weighted average price of $11.0939 to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Justin B. Klee, Co-Chief Executive Officer and Director of Amylyx Pharmaceuticals, Inc. (AMLX), reported a transaction involving the company's common stock.
• The transaction, dated January 6, 2026, was a disposition of 7,715 shares of common stock.
• The shares were sold at a weighted average price of $11.0939 per share, with individual sales ranging from $10.99 to $11.16.
• This sale was non-discretionary and executed to cover tax withholding obligations in connection with the vesting of restricted stock units.
• Following this transaction, Klee beneficially owns 3,317,586 shares of common stock.

Sentiment

Score: 5

Explanation: The transaction is a non-discretionary sale of shares to cover tax withholding obligations related to RSU vesting, which is a standard and expected event for executive compensation. It does not reflect a change in management's confidence or the company's operational performance, thus indicating a neutral sentiment.

Positives

• The vesting of restricted stock units (RSUs) indicates compensation for the Co-CEO, aligning management interests with shareholder value and reflecting ongoing executive retention.

Negatives

• No direct negatives identified as the sale was non-discretionary and solely for tax withholding purposes, not indicative of a lack of confidence in the company.

Future Outlook

N/A

Industry Context

N/A

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary sale for tax purposes, not indicative of a change in executive confidence or company fundamentals.

Key Dates

Recommendation

This Form 4 reports a non-discretionary sale of shares by a Co-CEO to cover tax obligations associated with restricted stock unit vesting. Such transactions are routine and do not typically signal a change in the company's fundamentals or management's outlook. Therefore, the filing itself does not warrant a change in investment recommendation, suggesting a 'hold' position based solely on this information.

Keywords

Amylyx Pharmaceuticals, AMLX, Form 4, Insider Transaction, Stock Sale, Executive Compensation, Restricted Stock Units, RSU Vesting, Justin B. Klee